Abivax Banks €130m To Advance Obefazimod
In Phase III For Ulcerative Colitis
The French biotech has attracted a raft of new US healthcare specialist backers in one of the biggest raises ever on the Euronext Paris but it will need millions more to complete the late-stage program for obefazimod.
You may also be interested in...
Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
France's Abivax Looks A Likely M&A Target
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.
Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.